

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pyrantel Pamoate / Ivermectin Formulation

Version  
6.1

Revision Date:  
18.06.2025

SDS Number:  
4893027-00022

Date of last issue: 14.04.2025  
Date of first issue: 17.09.2019

---

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

#### 1.1 Product identifier

Trade name : Pyrantel Pamoate / Ivermectin Formulation

#### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Substance/Mixture : Veterinary product

Recommended restrictions on use : Not applicable

#### 1.3 Details of the supplier of the safety data sheet

Company : MSD  
Drynam Road  
K67 P263 Dublin, Ireland

Telephone : +1-908-740-4000

E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

#### 1.4 Emergency telephone number

+1-908-423-6000

---

### SECTION 2: Hazards identification

#### 2.1 Classification of the substance or mixture

##### Classification (REGULATION (EC) No 1272/2008)

Specific target organ toxicity - single exposure, Category 2 H371: May cause damage to organs.

Specific target organ toxicity - repeated exposure, Category 2 H373: May cause damage to organs through prolonged or repeated exposure.

Short-term (acute) aquatic hazard, Category 1 H400: Very toxic to aquatic life.

Long-term (chronic) aquatic hazard, Category 1 H410: Very toxic to aquatic life with long lasting effects.

#### 2.2 Label elements

##### Labelling (REGULATION (EC) No 1272/2008)

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pyrantel Pamoate / Ivermectin Formulation

Version 6.1

Revision Date: 18.06.2025

SDS Number: 4893027-00022

Date of last issue: 14.04.2025  
Date of first issue: 17.09.2019

Hazard pictograms



Signal word

: Warning

Hazard statements

: H371 May cause damage to organs.  
H373 May cause damage to organs through prolonged or repeated exposure.  
H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements

: **Prevention:**

P264 Wash skin thoroughly after handling.  
P270 Do not eat, drink or smoke when using this product.  
P273 Avoid release to the environment.

**Response:**

P308 + P311 IF exposed or concerned: Call a POISON CENTER/ doctor.  
P391 Collect spillage.

**Storage:**

P405 Store locked up.

### Hazardous components which must be listed on the label:

Ivermectin

### Additional Labelling

The following percentage of the mixture consists of ingredient(s) with unknown hazards to the aquatic environment: 38.3 %

### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

## SECTION 3: Composition/information on ingredients

### 3.2 Mixtures

#### Components

Chemical name	CAS-No.	Classification	Concentration
---------------	---------	----------------	---------------

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pyrantel Pamoate / Ivermectin Formulation

Version  
6.1

Revision Date:  
18.06.2025

SDS Number:  
4893027-00022

Date of last issue: 14.04.2025  
Date of first issue: 17.09.2019

	EC-No. Index-No. Registration number		(% w/w)
4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1)	22204-24-6 244-837-1		>= 30 - < 50
Ivermectin	70288-86-7 274-536-0	Acute Tox. 2; H300 Acute Tox. 3; H311 STOT SE 1; H370 (Central nervous system) STOT RE 1; H372 (Central nervous system) Aquatic Acute 1; H400 Aquatic Chronic 1; H410  M-Factor (Acute aquatic toxicity): 10,000 M-Factor (Chronic aquatic toxicity): 10,000	>= 1 - < 2.5
Ethanol#	64-17-5 200-578-6 603-002-00-5	Flam. Liq. 2; H225 Eye Irrit. 2; H319  specific concentration limit Eye Irrit. 2; H319 >= 50 %	>= 0.1 - < 1

For explanation of abbreviations see section 16.

# Voluntarily-disclosed substance

## SECTION 4: First aid measures

### 4.1 Description of first aid measures

General advice

: In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders

: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled

: If inhaled, remove to fresh air.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pyrantel Pamoate / Ivermectin Formulation

Version  
6.1

Revision Date:  
18.06.2025

SDS Number:  
4893027-00022

Date of last issue: 14.04.2025  
Date of first issue: 17.09.2019

---

Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap as a precaution.  
Get medical attention if symptoms occur.

In case of eye contact : Flush eyes with water as a precaution.  
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting unless directed to do so by medical personnel.  
Get medical attention.  
Rinse mouth thoroughly with water.  
Never give anything by mouth to an unconscious person.

### 4.2 Most important symptoms and effects, both acute and delayed

Risks : May cause damage to organs.  
May cause damage to organs through prolonged or repeated exposure.

### 4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

---

## SECTION 5: Firefighting measures

### 5.1 Extinguishing media

Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

Unsuitable extinguishing media : None known.

### 5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides  
Nitrogen oxides (NO<sub>x</sub>)  
Sulphur oxides

### 5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pyrantel Pamoate / Ivermectin Formulation

Version  
6.1

Revision Date:  
18.06.2025

SDS Number:  
4893027-00022

Date of last issue: 14.04.2025  
Date of first issue: 17.09.2019

Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

## SECTION 6: Accidental release measures

### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

### 6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.  
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.  
Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

## SECTION 7: Handling and storage

### 7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Avoid breathing vapours.  
Do not swallow.  
Avoid contact with eyes.  
Avoid prolonged or repeated contact with skin.  
Wash skin thoroughly after handling.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pyrantel Pamoate / Ivermectin Formulation

Version 6.1	Revision Date: 18.06.2025	SDS Number: 4893027-00022	Date of last issue: 14.04.2025 Date of first issue: 17.09.2019
----------------	------------------------------	------------------------------	---

Hygiene measures	<p>Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the environment.</p> <p>If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.</p> <p>The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.</p>
------------------	--

### 7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers	: Keep in properly labelled containers. Store locked up. Store in accordance with the particular national regulations.
Advice on common storage	: Do not store with the following product types: Strong oxidizing agents Self-reactive substances and mixtures Organic peroxides Explosives Gases

### 7.3 Specific end use(s)

Specific use(s)	: No data available
-----------------	---------------------

## SECTION 8: Exposure controls/personal protection

### 8.1 Control parameters

#### Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1)	22204-24-6	TWA	250 µg/m3 (OEB 2)	Internal
Propylene glycol	57-55-6	OELV - 8 hrs (TWA) (particles)	10 mg/m3	IE OEL
		OELV - 8 hrs (TWA) (total (vapour and particles))	150 ppm 470 mg/m3	IE OEL
Ivermectin	70288-86-7	TWA	30 µg/m3 (OEB 3)	Internal

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pyrantel Pamoate / Ivermectin Formulation

Version  
6.1

Revision Date:  
18.06.2025

SDS Number:  
4893027-00022

Date of last issue: 14.04.2025  
Date of first issue: 17.09.2019

		Further information: Skin		
		Wipe limit	300 µg/100 cm <sup>2</sup>	Internal
Ethanol	64-17-5	OELV - 15 min (STEL)	1,000 ppm	IE OEL

### Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006

Substance name	End Use	Exposure routes	Potential health effects	Value
Glycerine	Workers	Inhalation	Long-term local effects	56 mg/m <sup>3</sup>
	Consumers	Ingestion	Long-term systemic effects	229 mg/kg bw/day
	Consumers	Inhalation	Long-term local effects	33 mg/m <sup>3</sup>
Propylene glycol	Workers	Inhalation	Long-term local effects	10 mg/m <sup>3</sup>
	Workers	Inhalation	Long-term systemic effects	168 mg/m <sup>3</sup>
	Consumers	Inhalation	Long-term local effects	10 mg/m <sup>3</sup>
Ethanol	Workers	Inhalation	Long-term systemic effects	50 mg/m <sup>3</sup>
	Workers	Skin contact	Long-term systemic effects	380 mg/m <sup>3</sup>
	Consumers	Inhalation	Long-term systemic effects	267 mg/kg bw/day

### Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006

Substance name	Environmental Compartment	Value
Ivermectin	Fresh water	0.000004 mg/l
	Marine water	0.000004 mg/l
Glycerine	Fresh water	0.885 mg/l
	Marine water	0.0885 mg/l
Propylene glycol	Intermittent use/release	8.85 mg/l
	Sewage treatment plant	1000 mg/l
Ethanol	Fresh water sediment	3.3 mg/kg dry weight (d.w.)
	Marine sediment	0.33 mg/kg dry weight (d.w.)
Ethanol	Soil	0.141 mg/kg dry weight (d.w.)
	Fresh water	260 mg/l
Propylene glycol	Freshwater - intermittent	183 mg/l
	Marine water	26 mg/l
Propylene glycol	Sewage treatment plant	20000 mg/l
	Fresh water sediment	572 mg/kg dry weight (d.w.)
Propylene glycol	Marine sediment	57.2 mg/kg dry weight (d.w.)

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pyrantel Pamoate / Ivermectin Formulation

Version  
6.1

Revision Date:  
18.06.2025

SDS Number:  
4893027-00022

Date of last issue: 14.04.2025  
Date of first issue: 17.09.2019

	Soil	50 mg/kg dry weight (d.w.)
Ethanol	Fresh water	0.96 mg/l
	Freshwater - intermittent	2.75 mg/l
	Marine water	0.79 mg/l
	Sewage treatment plant	580 mg/l
	Fresh water sediment	3.6 mg/kg dry weight (d.w.)
	Marine sediment	2.9 mg/kg dry weight (d.w.)
	Soil	0.63 mg/kg dry weight (d.w.)
	Oral (Secondary Poisoning)	380 mg/kg food

### 8.2 Exposure controls

#### Engineering measures

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

#### Personal protective equipment

Eye/face protection	: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Hand protection	
Material	: Chemical-resistant gloves
Remarks	: Consider double gloving.
Skin and body protection	: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Respiratory protection	: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Filter should conform to I.S. EN 14387
Filter type	: Combined particulates and organic vapour type (A-P)

### SECTION 9: Physical and chemical properties

#### 9.1 Information on basic physical and chemical properties

Physical state	: paste
----------------	---------

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pyrantel Pamoate / Ivermectin Formulation

Version 6.1	Revision Date: 18.06.2025	SDS Number: 4893027-00022	Date of last issue: 14.04.2025 Date of first issue: 17.09.2019
----------------	------------------------------	------------------------------	---

---

Colour : yellow

Odour : No data available

Odour Threshold : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flammability (solid, gas) : No data available

Flammability (liquids) : Not applicable

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Flash point : Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available

pH : No data available

Viscosity

Viscosity, kinematic : Not applicable

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-octanol/water : Not applicable

Vapour pressure : Not applicable

Relative density : No data available

Density : No data available

Relative vapour density : Not applicable

Particle characteristics

Particle size : Not applicable

### 9.2 Other information

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pyrantel Pamoate / Ivermectin Formulation

Version 6.1 Revision Date: 18.06.2025 SDS Number: 4893027-00022 Date of last issue: 14.04.2025  
Date of first issue: 17.09.2019

---

Explosives	: Not explosive
Oxidizing properties	: The substance or mixture is not classified as oxidizing.
Evaporation rate	: Not applicable
Molecular weight	: No data available

---

## SECTION 10: Stability and reactivity

### 10.1 Reactivity

Not classified as a reactivity hazard.

### 10.2 Chemical stability

Stable under normal conditions.

### 10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

### 10.4 Conditions to avoid

Conditions to avoid : None known.

### 10.5 Incompatible materials

Materials to avoid : Oxidizing agents

### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

---

## SECTION 11: Toxicological information

### 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure : Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

#### Product:

Acute oral toxicity	: Acute toxicity estimate: > 2,000 mg/kg Method: Calculation method
Acute dermal toxicity	: Acute toxicity estimate: > 2,000 mg/kg Method: Calculation method

#### Components:

**4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):**

## SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Pyrantel Pamoate / Ivermectin Formulation**

Version Revision Date: SDS Number: Date of last issue: 14.04.2025  
6.1 18.06.2025 4893027-00022 Date of first issue: 17.09.2019

Acute oral toxicity : LD50 (Rat): > 24,000 mg/kg  
LD50 (Mouse): > 24,000 mg/kg  
LD50 (Dog): 2,000 mg/kg

## Ivermectin:

Acute oral toxicity : LD50 (Rat): 50 mg/kg  
LD50 (Mouse): 25 mg/kg  
LD50 (Monkey): > 24 mg/kg  
Target Organs: Central nervous system  
Symptoms: Vomiting, Dilatation of the pupil  
Remarks: No mortality observed at this dose.

Acute inhalation toxicity : LC50 (Rat): 5.11 mg/l  
Exposure time: 1 h  
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): 406 mg/kg  
LD50 (Rat): > 660 mg/kg

## Ethanol:

Acute oral toxicity	:	LD50 (Rat): 10,470 mg/kg Method: OECD Test Guideline 401
Acute inhalation toxicity	:	LC50 (Rat, male): 116.9 mg/l Exposure time: 4 h Test atmosphere: vapour
Acute dermal toxicity	:	LD50 (Rabbit): > 15,800 mg/kg

## Skin corrosion/irritation

Not classified based on available information.

## Components:

## Ivermectin:

Species : Rabbit  
Result : No skin irritation

## Ethanol:

Species : Rabbit  
Method : OECD Test Guideline 404  
Result : No skin irritation

### **Serious eye damage/eye irritation**

Not classified based on available information.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pyrantel Pamoate / Ivermectin Formulation

Version  
6.1

Revision Date:  
18.06.2025

SDS Number:  
4893027-00022

Date of last issue: 14.04.2025  
Date of first issue: 17.09.2019

---

### Components:

#### **Ivermectin:**

Species : Rabbit  
Result : Mild eye irritation

#### **Ethanol:**

Species : Rabbit  
Method : OECD Test Guideline 405  
Result : Irritation to eyes, reversing within 21 days

### **Respiratory or skin sensitisation**

#### **Skin sensitisation**

Not classified based on available information.

#### **Respiratory sensitisation**

Not classified based on available information.

### Components:

#### **Ivermectin:**

Exposure routes : Dermal  
Species : Humans  
Result : Does not cause skin sensitisation.

#### **Ethanol:**

Test Type : Mouse ear swelling test (MEST)  
Exposure routes : Skin contact  
Species : Mouse  
Result : negative

### **Germ cell mutagenicity**

Not classified based on available information.

### Components:

#### **4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

#### **Ivermectin:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)  
Test system: human diploid fibroblasts  
Result: negative

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pyrantel Pamoate / Ivermectin Formulation

Version  
6.1

Revision Date:  
18.06.2025

SDS Number:  
4893027-00022

Date of last issue: 14.04.2025  
Date of first issue: 17.09.2019

---

Test Type: Mouse Lymphoma  
Result: negative

### Ethanol:

Genotoxicity in vitro

: Test Type: Bacterial reverse mutation assay (AMES)  
Method: OECD Test Guideline 471  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Method: OECD Test Guideline 476  
Result: negative

Test Type: Chromosome aberration test in vitro  
Result: negative

Genotoxicity in vivo

: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Rat  
Application Route: Ingestion  
Result: negative

### Carcinogenicity

Not classified based on available information.

### Components:

#### Ivermectin:

Species : Rat  
Application Route : Oral  
NOAEL : 1.5 mg/kg body weight  
Result : negative  
Remarks : Based on data from similar materials

Species : Mouse  
Application Route : Oral  
NOAEL : 2.0 mg/kg body weight  
Result : negative  
Remarks : Based on data from similar materials

### Reproductive toxicity

Not classified based on available information.

### Components:

#### 4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: NOAEL: 3,000 mg/kg body weight  
Result: No effects on fertility and early embryonic develop-

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pyrantel Pamoate / Ivermectin Formulation

Version  
6.1

Revision Date:  
18.06.2025

SDS Number:  
4893027-00022

Date of last issue: 14.04.2025  
Date of first issue: 17.09.2019

---

ment were detected.

Test Type: Embryo-foetal development

Species: Rabbit

Application Route: Oral

Developmental Toxicity: NOAEL: 1,000 mg/kg body weight

Result: No effects on fertility and early embryonic development were detected.

### Ivermectin:

Effects on fertility

: Test Type: Fertility

Species: Rat

Application Route: Oral

Fertility: NOAEL: 0.6 mg/kg body weight

Result: Animal testing did not show any effects on fertility.

Effects on foetal development

: Test Type: Development

Species: Mouse

Application Route: Oral

Developmental Toxicity: NOAEL: 0.2 mg/kg body weight

Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

Test Type: Development

Species: Rat

Application Route: Oral

Developmental Toxicity: LOAEL: 0.4 mg/kg body weight

Result: Embryotoxic effects and adverse effects on the offspring were detected.

Remarks: The mechanism or mode of action may not be relevant in humans.

Test Type: Development

Species: Rabbit

Application Route: Oral

Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

### Ethanol:

Effects on fertility

: Test Type: Two-generation reproduction toxicity study

Species: Mouse

Application Route: Ingestion

Result: negative

### STOT - single exposure

May cause damage to organs.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pyrantel Pamoate / Ivermectin Formulation

Version  
6.1

Revision Date:  
18.06.2025

SDS Number:  
4893027-00022

Date of last issue: 14.04.2025  
Date of first issue: 17.09.2019

---

### Components:

#### **Ivermectin:**

Target Organs : Central nervous system  
Assessment : Causes damage to organs.

#### **STOT - repeated exposure**

May cause damage to organs through prolonged or repeated exposure.

### Components:

#### **Ivermectin:**

Target Organs : Central nervous system  
Assessment : Causes damage to organs through prolonged or repeated exposure.

### **Repeated dose toxicity**

### Components:

#### **4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):**

Species : Dog  
NOAEL : 10 mg/kg  
LOAEL : 30 mg/kg  
Application Route : Ingestion  
Exposure time : 3 d  
Remarks : No significant adverse effects were reported

Species : Dog  
NOAEL : 600 mg/kg  
Application Route : Oral  
Exposure time : 19 d  
Remarks : No significant adverse effects were reported

Species : Dog  
NOAEL : 600 mg/kg  
Application Route : Oral  
Exposure time : 30 d  
Remarks : No significant adverse effects were reported

Species : Dog  
NOAEL : 600 mg/kg  
Application Route : Oral  
Exposure time : 90 d  
Remarks : No significant adverse effects were reported

#### **Ivermectin:**

Species : Dog  
NOAEL : 0.5 mg/kg  
LOAEL : 1 mg/kg  
Application Route : Oral

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pyrantel Pamoate / Ivermectin Formulation

Version 6.1	Revision Date: 18.06.2025	SDS Number: 4893027-00022	Date of last issue: 14.04.2025 Date of first issue: 17.09.2019
----------------	------------------------------	------------------------------	---

Exposure time : 14 Weeks  
Target Organs : Central nervous system  
Symptoms : Dilatation of the pupil, Tremors, Lack of coordination, anorexia

Species : Monkey  
NOAEL : 1.2 mg/kg  
Application Route : Oral  
Exposure time : 2 Weeks  
Remarks : No significant adverse effects were reported

Species : Rat  
NOAEL : 0.4 mg/kg  
LOAEL : 0.8 mg/kg  
Application Route : Oral  
Exposure time : 3 Months  
Target Organs : spleen, Bone marrow, Kidney

### **Ethanol:**

Species : Rat  
NOAEL : 1,730 mg/kg  
LOAEL : 3,200 mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days

### **Aspiration toxicity**

Not classified based on available information.

## 11.2 Information on other hazards

### **Endocrine disrupting properties**

Not classified based on available information.

### **Product:**

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

### **Experience with human exposure**

#### **Components:**

##### **4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):**

Ingestion : Symptoms: Abdominal pain, Nausea, Vomiting, Diarrhoea, Headache, Dizziness, Fever

#### **Ivermectin:**

Skin contact : Remarks: Can be absorbed through skin.  
Eye contact : Remarks: May irritate eyes.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pyrantel Pamoate / Ivermectin Formulation

Version 6.1	Revision Date: 18.06.2025	SDS Number: 4893027-00022	Date of last issue: 14.04.2025 Date of first issue: 17.09.2019
----------------	------------------------------	------------------------------	---

Ingestion	: Symptoms: Drowsiness, Dilatation of the pupil, Tremors, Vomiting, anorexia, Lack of coordination
-----------	--

## SECTION 12: Ecological information

### 12.1 Toxicity

#### Components:

**4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):**

#### **Ecotoxicology Assessment**

Acute aquatic toxicity : Toxic effects cannot be excluded

Chronic aquatic toxicity : Toxic effects cannot be excluded

#### **Ivermectin:**

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 0.003 mg/l  
Exposure time: 96 h

LC50 (Lepomis macrochirus (Bluegill sunfish)): 0.0048 mg/l  
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0.000025 mg/l  
Exposure time: 48 h

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 9.1 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 9.1 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

M-Factor (Acute aquatic toxicity) : 10,000

M-Factor (Chronic aquatic toxicity) : 10,000

#### **Ethanol:**

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 14,200 mg/l  
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Ceriodaphnia dubia (water flea)): 5,012 mg/l  
Exposure time: 48 h

Toxicity to algae/aquatic plants : ErC50 (Chlorella vulgaris (Fresh water algae)): 275 mg/l  
Exposure time: 72 h

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pyrantel Pamoate / Ivermectin Formulation

Version 6.1 Revision Date: 18.06.2025 SDS Number: 4893027-00022 Date of last issue: 14.04.2025 Date of first issue: 17.09.2019

---

EC10 (Chlorella vulgaris (Fresh water algae)): 11.5 mg/l  
Exposure time: 72 h

Toxicity to microorganisms : EC50 (Protozoa): 5,800 mg/l  
Exposure time: 4 h

Toxicity to fish (Chronic toxicity) : NOEC: >= 79 mg/l  
Exposure time: 100 d  
Species: Oryzias latipes (Japanese medaka)

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 9.6 mg/l  
Exposure time: 9 d  
Species: Daphnia magna (Water flea)

### 12.2 Persistence and degradability

#### Components:

##### **Ivermectin:**

Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 50 %  
Exposure time: 240 d

##### **Ethanol:**

Biodegradability : Result: Readily biodegradable.  
Biodegradation: 84 %  
Exposure time: 20 d

### 12.3 Bioaccumulative potential

#### Components:

##### **Ivermectin:**

Bioaccumulation : Bioconcentration factor (BCF): 74

Partition coefficient: n-octanol/water : log Pow: 3.22

##### **Ethanol:**

Partition coefficient: n-octanol/water : log Pow: -0.35

### 12.4 Mobility in soil

#### Components:

##### **Ethanol:**

Distribution among environmental compartments : log Koc: 0.2

### 12.5 Results of PBT and vPvB assessment

#### Product:

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pyrantel Pamoate / Ivermectin Formulation

Version 6.1	Revision Date: 18.06.2025	SDS Number: 4893027-00022	Date of last issue: 14.04.2025 Date of first issue: 17.09.2019
----------------	------------------------------	------------------------------	---

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

### 12.6 Endocrine disrupting properties

#### Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

### 12.7 Other adverse effects

No data available

## SECTION 13: Disposal considerations

### 13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.  
Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

## SECTION 14: Transport information

### 14.1 UN number or ID number

**ADN** : UN 3077  
**ADR** : UN 3077  
**RID** : UN 3077  
**IMDG** : UN 3077  
**IATA** : UN 3077

### 14.2 UN proper shipping name

**ADN** : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.  
(Ivermectin)  
**ADR** : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.  
(Ivermectin)

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pyrantel Pamoate / Ivermectin Formulation

Version 6.1 Revision Date: 18.06.2025 SDS Number: 4893027-00022 Date of last issue: 14.04.2025  
Date of first issue: 17.09.2019

---

<b>RID</b>	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ivermectin)
<b>IMDG</b>	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ivermectin)
<b>IATA</b>	:	Environmentally hazardous substance, solid, n.o.s. (Ivermectin)

### 14.3 Transport hazard class(es)

	Class	Subsidiary risks
<b>ADN</b>	:	9
<b>ADR</b>	:	9
<b>RID</b>	:	9
<b>IMDG</b>	:	9
<b>IATA</b>	:	9

### 14.4 Packing group

<b>ADN</b>		
Packing group	:	III
Classification Code	:	M7
Hazard Identification Number	:	90
Labels	:	9
<b>ADR</b>		
Packing group	:	III
Classification Code	:	M7
Hazard Identification Number	:	90
Labels	:	9
Tunnel restriction code	:	(-)
<b>RID</b>		
Packing group	:	III
Classification Code	:	M7
Hazard Identification Number	:	90
Labels	:	9
<b>IMDG</b>		
Packing group	:	III
Labels	:	9
EmS Code	:	F-A, S-F
<b>IATA (Cargo)</b>		
Packing instruction (cargo aircraft)	:	956
Packing instruction (LQ)	:	Y956
Packing group	:	III
Labels	:	Miscellaneous

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pyrantel Pamoate / Ivermectin Formulation

Version  
6.1

Revision Date:  
18.06.2025

SDS Number:  
4893027-00022

Date of last issue: 14.04.2025  
Date of first issue: 17.09.2019

---

### IATA (Passenger)

Packing instruction (passenger aircraft) : 956  
Packing instruction (LQ) : Y956  
Packing group : III  
Labels : Miscellaneous

### 14.5 Environmental hazards

#### ADN

Environmentally hazardous : yes

#### ADR

Environmentally hazardous : yes

#### RID

Environmentally hazardous : yes

#### IMDG

Marine pollutant : yes

### IATA (Passenger)

Environmentally hazardous : yes

### IATA (Cargo)

Environmentally hazardous : yes

### 14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

### 14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

---

## SECTION 15: Regulatory information

### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII)

: Conditions of restriction for the following entries should be considered: Number on list 75: If you intend to use this product as tattoo ink, please contact your vendor.

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pyrantel Pamoate / Ivermectin Formulation

Version  
6.1

Revision Date:  
18.06.2025

SDS Number:  
4893027-00022

Date of last issue: 14.04.2025  
Date of first issue: 17.09.2019

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).	determine whether an entry is applicable to the placing on the market or not.
Regulation (EU) No 2024/590 on substances that deplete the ozone layer	: Not applicable
Regulation (EU) 2019/1021 on persistent organic pollutants (recast)	: Not applicable
Regulation (EU) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals	: Not applicable
REACH - List of substances subject to authorisation (Annex XIV)	: Not applicable
Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.	

E1	ENVIRONMENTAL HAZARDS	Quantity 1 100 t	Quantity 2 200 t
----	-----------------------	---------------------	---------------------

### Other regulations:

Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.

Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

### The components of this product are reported in the following inventories:

DSL	: not determined
AICS	: not determined
IECSC	: not determined

## 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

## SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

### Full text of H-Statements

H225	: Highly flammable liquid and vapour.
H300	: Fatal if swallowed.
H311	: Toxic in contact with skin.
H319	: Causes serious eye irritation.
H370	: Causes damage to organs if swallowed.
H372	: Causes damage to organs through prolonged or repeated exposure if swallowed.
H400	: Very toxic to aquatic life.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pyrantel Pamoate / Ivermectin Formulation

Version 6.1	Revision Date: 18.06.2025	SDS Number: 4893027-00022	Date of last issue: 14.04.2025 Date of first issue: 17.09.2019
----------------	------------------------------	------------------------------	---

H410 : Very toxic to aquatic life with long lasting effects.

### Full text of other abbreviations

Acute Tox.	: Acute toxicity
Aquatic Acute	: Short-term (acute) aquatic hazard
Aquatic Chronic	: Long-term (chronic) aquatic hazard
Eye Irrit.	: Eye irritation
Flam. Liq.	: Flammable liquids
STOT RE	: Specific target organ toxicity - repeated exposure
STOT SE	: Specific target organ toxicity - single exposure
IE OEL	: Ireland. List of Chemical Agents and Carcinogens with Occupational Exposure Limit Values - Code of Practice, Schedule 1 and 2
IE OEL / OELV - 8 hrs (TWA)	: Occupational exposure limit value (8-hour reference period)
IE OEL / OELV - 15 min (STEL)	: Occupational exposure limit value (15-minute reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

### Further information

Sources of key data used to compile the Safety Data : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pyrantel Pamoate / Ivermectin Formulation

Version  
6.1

Revision Date:  
18.06.2025

SDS Number:  
4893027-00022

Date of last issue: 14.04.2025  
Date of first issue: 17.09.2019

---

Sheet

cy, <http://echa.europa.eu/>

### Classification of the mixture:

STOT SE 2	H371
STOT RE 2	H373
Aquatic Acute 1	H400
Aquatic Chronic 1	H410

### Classification procedure:

Calculation method
Calculation method
Calculation method
Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN